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Small intestineCongenital Short Bowel Syndrome (CSBS) is a rare gastrointestinal disorder inwhich themean length of the small
intestine is substantially reducedwhen compared to its normal counterpart. Familieswith several affectedmem-
bers have been described and CSBS has been suggested to have a genetic basis. Recently, our group found muta-
tions in CLMP as the cause of the recessive form of CSBS, andmutations in FLNA as the cause of the X-linked form
of the disease. These ﬁndings have improved the quality of genetic counselling for CSBS patients and made pre-
natal diagnostics possible. Moreover, they provided a reliable starting point to further investigate the pathogen-
esis of CSBS, and to better understand the development of the small intestine. In this review, we present our
current knowledge on CSBS and discuss hypotheses on how the recent genetic ﬁndings can help understand
the cause of CSBS.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Short bowel syndrome (SBS) refers to the sum of functional alter-
ations that are the result of a critical reduction in the length of the intes-
tine. In the absence of adequate treatment, SBS presents as chronic
diarrhoea, chronic dehydration, malnutrition, weight loss, and nutri-
ment and electrolyte deﬁciency. In most cases, SBS occurs as a result
of surgical intervention for other diseases, such as necrotizing enteroco-
litis and intestinal atresia. However, in a small number of cases the small
intestine is already shortened at birth, leading to a diagnosis of Congen-
ital Short Bowel Syndrome (CSBS). CSBS is a heritable gastrointestinal
disorder, ﬁrst described by Hamilton et al. in 1969 [1]. For many years
the underlying genetic cause of the disease was unknown. Recently,
mutations in CLMP were identiﬁed to cause the autosomal recessive
form of CSBS [2], and mutations in FLNA as the cause of the X-linked
form of the disease [3]. Theseﬁndings brought new insights into disease
pathogenesis, but the mechanisms in which CLMP and FLNA contribute
to intestinal elongation are still unknown.
In this reviewwe describe the clinical aspects of CSBS, the recent ge-
netic ﬁndings, and the aetiological aspects of this gastrointestinal disor-
der. Moreover, we hypothesise about the mechanisms underlying the
development of CSBS and the signalling pathways that might be essen-
tial for development and elongation of the small intestine, based in pre-
viously described mouse models.Genetics, Erasmus University
therlands.
tra).2. Clinical presentation
CSBS patients are characterized by the presence of a substantially
shortened small intestine at birth, approximately 50 cm, when com-
pared to 250 cm inneonates delivered at term (N35weeks of gestation).
As a consequence, they have a reduced absorptive surface of the small
intestine and suffer frommalabsorption [4]. CSBS can be detected by ra-
diography, but the diagnosis is usually done by laparotomy. Patients
with CSBS often present within a few days after birth with bile-
stained vomiting and diarrhoea or failure to thrive, but in some cases
the diagnosis has beenmade later in life when an exploratory laparoto-
my was performed for signiﬁcant gastrointestinal complaint [5].
Malrotation of the bowel is always present, and although this can
point to an independent developmental defect, it can also be just a con-
sequence of the shortened small intestine. The cecum is often posi-
tioned in the left upper quadrant of the abdomen close to the splenic
ﬂexure [1,6–10], but it can also be located in the lower left quadrant of
the abdomen when nonrotation of the bowel is observed [11]. In three
reported patients the appendix was absent [4,7,12], and volvulus was
found in four patients [13,14]. In a few cases, not only the small intestine
was shortened, but also the colon was affected [4,7,12,14]. Another gas-
trointestinal anomaly that was described in ten CSBS patients is hyper-
trophic pyloric stenosis [10,13,15–18]. However, it has been suggested
that hypertrophic pyloric stenosis is not part of the general develop-
mental defect of the gastrointestinal tract, but a physiological conse-
quence from the attempts of the remnant small intestine to slow
down the gastric emptying and improve absorptive capacity. CSBS pa-
tients usually have normal intellectual ability [19,20] and do not present
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ductus arteriosuswas found [17,18], and in two patientsminor dysmor-
phic features were reported [9,21].
3. Histological ﬁndings in CSBS patients
Based on the literature available, it is difﬁcult to assess if abnormal
peristalsis is associated with CSBS pathogenesis, or if it is an indepen-
dent event to the presence of a short bowel [3,22,23]. In most CSBS pa-
tients the bowel wall seems macroscopically normal, but an abnormal
histology has been described in some patients. Tanner et al. performed
silver staining in patients' material and found an abnormally high num-
ber of neurons in the ganglia [13]. This result led the authors to suggest
that the normal fall-out of ganglion cells does not occur in CSBS patients.
They also found that the neuronal nuclei showed clumped chromatin,
which is characteristic for neuroblasts, and the intrinsic argyrophilic
ganglion cells were absent or reduced in number. However, these re-
sults lacked a quantitative analysis of the data and comparison to suit-
able controls to support hyperganglionosis as the cause of reduced
intestinal motility. In an independent study, Schalamon et al. also ob-
served an abnormal bowelwall with signs of neuronal intestinal dyspla-
sia in two siblings with CSBS [2]. In another CSBS patient heterotopic
gastric mucosawas found [23]. Conversely, in other cases, no abnormal-
ities of the nerves plexus were seen on routine acetylcholinesterase
staining [1,6,12,18,24–26]. Nezelof et al. described three cases with sev-
eral congenital malformations, which included a shortened small intes-
tine and heterotopia. In these patients a normal myenteric plexus was
observed by cytoenzymatic and silver stainings [16]. In another study,
Kapur et al. reported an extensive pathologic analysis performed on in-
testinal tissue collected from ﬁve male patients diagnosed with CSBS
and X-linked intestinal pseudo-obstruction. They observed that these
patients had diffused abnormal layering of the small intestinal smooth
muscle, in which themuscularis propria layer was formed by three per-
pendicular muscle laminae, instead of two. Such abnormal structure
was restricted to the small intestine without any extension to theFig. 1. Histological characteristics and functcolon [27]. Based on this report, a myopathic cause for the abnormal in-
testinal peristalsis found in CSBS patients was suggested. Despite the
contradictory results, these histological ﬁndings can account for themo-
tility abnormalities described in CSBS patients, but to date it still re-
mains unclear whether the reduced peristalsis observed in these
patients results from a neuronal or a myopathic defect.
To our knowledge, there has never been a precise histological conﬁr-
mation to deﬁnewhich part of the small intestine is affected in CSBS pa-
tients. It is possible that every part of the small intestine is shortened in
general, but one cannot rule out the possibility that only one speciﬁc
part of the small intestine is affected. If this is the case, a correlation be-
tween the type of the remaining small intestine and prognosis of CSBS
patients can be established. Since different parts of the small intestine
have different histology and function (Fig. 1), it would not be surprising
that depending on the region affected, different degrees of severity for
CSBS could exist. Findings in acquired SBS cases support this idea, as it
has been shown that the residual length of the jejunum and ileum
with the presence of ileocecal valve (ICV), are important factors to de-
termine the outcome of the disease [28]. Therefore, we believe that
identifying the part of the small intestine that is affected in CSBS pa-
tients should be a priority.
4. Treatment management and outcome
To date, there is no cure for CSBS and patients need total parenteral
nutrition for long-term survival until sufﬁcient bowel length and func-
tions are gained. In some cases, total parenteral nutrition has to be con-
tinued for the ﬁrst two years of life [6,9], and oral feeding is introduced
gradually. With time, the function of the remnant small intestine in
CSBS patients improves, both in length and absorption capacity, leading
to better absorption of fat and vitamin B12 [1,6,14]. The weight
and height of CSBS patients are frequently below the 50th percentile
[1,6,18,20,29], but no nutritional deﬁciencies are observed [6,9,30].
Parenteral nutrition has brought a new lease of life to an otherwise
fatal condition. However, its use is often associated with very highion of each part of the small intestine.
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transplantation can also be considered, but due to its relatively poor
overall survival it is viewed only as a last resort treatment option. It
has been recommended that CSBS patients should bemanaged in amul-
tidisciplinary manner in a centre specialized in the care of childrenwith
intestinal failure [9], but despite considerable efforts to improve treat-
ment, most patients die of starvation or sepsis within the ﬁrst few
days of life, and only a quarter of the reported patients survived for
more than one year (Table 1).
5. Disease aetiology
To understand the causes underlying the pathogenesis of CSBS, a
better understanding of the mechanisms involved in the development
of the small intestine is required. In this section,we describe the embry-
onic events necessary for intestinal growth and elongation.
During embryogenesis, the primitive gut tube is divided in three re-
gions: the foregut, the midgut and the hindgut, each of them with their
own arterial supply (the celiac artery, the superior mesenteric artery
and the inferior mesenteric artery, respectively). The small intestine
(jejunum and ileum) originates from the midgut, as well as the distalTable 1
Overview of reported cases with CSBS as the main symptom.
Sex Small bowel length (cm) Reference Year of publication Age at tim
F 40 [1] 1969 4 months
F 30 [1] 1969 Unknown
M 30 [8] 1970 3 months
F 42 [14] 1973 3 days
M 70 [15] 1973 7 weeks
F 25 [17] 1974 1 month
M 70 [17] 1974 Unknown
M 45 [17] 1974 15 days
F 40 [17] 1974 5 days
M 106 [24] 1974 22 days
M 75 [7] 1976 6 days
M 70 [16] 1976 18 days
M Unknown [16] 1976 7 days
M 50 [16] 1976 15 days
M 24 [11] 1984 32 days
M 27 [11] 1984 2 days
F 45 [39] 1984 Unknown
F 45 [39] 1984 1 day
M 72 [18] 1984 6 weeks
M 65 [18] 1984 18 days
M 24 [40] 1985 3 days
M 27 [40] 1985 2 days
M 45 [7] 1985 5 weeks
M 69 [6] 1986 5 weeks
M 112 [42] 1990 1 month
M 70 [42] 1990 6 hours
M 237a [42] 1990 3 months
F 54 [19] 1991 2 months
F 30 [26] 1993 2 days
M 39 [26] 1993 Unknown
F 30 [26] 1993 Unknown
F 30 [43] 1996 1 day
F 50 [21] 1997 1 day
F 25 [12] 1998 4 days
M 47 [20] 1999 9 days
M 42 [25] 2001 2 days
F 51 [25] 2001 3 days
M 95 [25] 2001 2 months
M 35 [25] 2001 2 days
M 228.6b [5] 2002 15 years
M 56 [4] 2004 4 months
F 20 [29] 2004 4 days
F 30 [9] 2006 5 days
M 50 [30] 2008 6 weeks
M 20–25 [44] 2010 26 days
M Unknown [3] 2013 Unknown
a At 14 years of age.
b At 15 years of age.duodenum, cecum, ascending colon, and the proximal two-thirds of
the transverse colon. In the ﬁfth week of embryonic development the
future ileum is elongating rapidly (Fig. 2), but as the abdominal cavity
grows slower, the midgut forms an anteroposterior loop called the pri-
mary intestinal loop. The cranial limb of this loop includes the ileum and
the caudal limb includes the ascending and transverse colons. In the
sixth week of development, the primary intestinal loop herniates into
the umbilicus forced by its own elongation and growth of other abdom-
inal organs. At this time the loop rotates 90° counter clockwise around
the axis of the superior mesenteric artery. The future ileum is now
lying on the right, and the cecum on the left. The cecum and the appen-
dix continue to differentiate and the small intestine elongates further
forming the jejunal–ileal loops. The attached mesentery accompanies
this intestinal growth but it does so at a lower rate. Recent studies
have shown that it is the differential growth rate between the intestine
and themesentery that creates speciﬁc patterns of looping and rotation
of the gut in different species [31]. Therefore, any disturbance of this dif-
ferential growth rate may lead to abnormal growth patterns and result
in intestinal malrotation. During the tenth week of gestation, the intes-
tinal loop returns rapidly to the abdominal cavity. The small intestine
returns ﬁrst and the ascending and transverse colons follow later. It ise of presentation Age at death Familial Consanguinity
Alive at time of publication Yes No
1 month Yes No
5 months Unknown Unknown
35 days No No
5 months Unknown Unknown
21 days Yes Unknown
4 days Yes Unknown
7 months Yes Yes
2 months No No
25 days Yes Yes
6 months No No
22 days Yes No
16 days Yes No
7 months Yes No
55 days Yes No
5 months Yes No
3 months Yes Yes
6 weeks Yes Yes
Alive at time of publication Yes No
2 months Yes No
55 days Yes No
5 months Yes No
2 months No No
Alive at time of publication No Yes
6 weeks Yes No
6 months Yes No
Alive at time of publication Yes No
Alive at time of publication No No
4 months Yes No
6 months Yes No
2 months No No
Alive at time of publication No No
Alive at time of publication No No
6 months No No
Alive at time of publication Yes Yes
5 months Yes No
2 weeks Yes No
Alive at time of publication No Yes
2 months Yes No
Alive at time of publication No No
Alive at time of publication No No
Alive at time of publication No No
Alive at time of publication Yes No
Alive at time of publication Yes Unknown
1 month No No
Alive at time of publication Yes No
Fig. 2. Embryogenesis of the human small intestine.
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the abdominal cavity and a relatively decrease in the size of the liver
and kidneys seem to play an important role. To reach the deﬁnitive con-
ﬁguration of the small and large intestines, the intestinal loop rotates
another 180° counter-clockwise [32–34].
Following this intricate growth, looping and rotation of the gut, in-
testinal patterning and regionalization takes place. All intestinal organs
derived from the foregut, midgut and hindgut consist of similar layers,
which include mucosa, muscularis mucosa, submucosa, submucosal
plexus, muscularis propria, myenteric plexus and serosal layer. Forma-
tion of these layers requires extensive proliferation and differentiation
of cells that compose the epithelial andmuscle of the intestine. The neu-
ronal network responsible for intestinal innervation is mainly formed
by enteric neural crest cells (ENCCs) that migrate from the neural tube
in a rostral to caudal direction to promote neuronal colonization of the
intestinal tract [35]. Interestingly, cell differentiation and radial pattern-
ing of the gut are largely dictated by signals exchanged between the dif-
ferent cell types that constitute the various layers. For example, the
hedgehog signalling initiated in the intestinal epithelium affects cell
proliferation and differentiation of cells derived from all embryonic
layers (endoderm, mesoderm and ectoderm), playing an important
role in the establishment of the villus-crypt patterning, smooth muscle
cells' proliferation, and ENCCs' proliferation, differentiation and migra-
tion [36,37]. Several other morphogenic pathways regulate cellular in-
teractions and are thus, necessary for intestinal elongation. These
pathways are discussed further in Section 8 of this review. Nonetheless,
it is important to acknowledge here the existence of such interactions,
since the gut abnormalities found in CSBS patients may well arise due
to dysregulation of these morphogenic pathways.
6. Genetics
Familial occurrence of CSBS was described in the very ﬁrst case re-
port in 1969. Hamilton et al. reported a French-Canadian couple who
were not related and who had ﬁve daughters, two of them diagnosed
with CSBS. One of the affected girls died at the age of 1 month and
1 week, and prior to death a laparotomy showed a small intestine of
30 cm in length [1]. More case reports followed and a familial occur-
rence was described in approximately 60% of the cases published in
the literature. In most of these cases siblings were affected, and in ap-
proximately 25% of the cases the parents were consanguineous
(Table 1). It has therefore been suggested by several authors that genet-
ic factors were involved in CSBS and an autosomal recessive pattern of
inheritance was proposed by many of them [6,10,17,19,25,38–40].
However, since only boys were found affected in some families, an
X-linked pattern of inheritance has also been suggested [16,18,41,42].In this section, we focus on the genetic ﬁndings described in CSBS
patients.
6.1. Chromosomal abnormalities
Two patients have been described with chromosomal abnormalities.
Hou et al. reported a female patient with multiple congenital anomalies,
such as congenital short bowel,malrotation, and patent ductus arteriosus,
in addition to major malformations, such as left upper amelia,
dextrocardia and asplenia. Chromosomal investigation of this patient
showed a mosaic pattern with complex rearrangements of chromosome
4: 85% of the peripheral lymphocytes showed a normal female cell line
(46,XX), while 12% of the cells showed a pattern with one normal chro-
mosome 4 and a ring chromosome 4 (46,XX-4,+r(4)(p16➔q22.3). The
ring caused a deletion of the long arm of chromosome 4. Approximately
4% of the cells from this patient had a patternwith partial trisomy of chro-
mosome 4: one normal chromosome 4, one ring chromosome 4 and one
chromosome 4 with the same deletion of the long arm of chromosome 4
(47,XX,4,+r(4)(p16➔q22.3),+del(4)(pter➔q22.3:)) [43]. De Backer
et al. also described a female CSBS patient with a de novo balanced trans-
location between chromosome 2 and 11 (46,XX,t(2,11)(q32.2,p12)) [21].
However, no functional implications of these chromosomal abnormalities
have been reported in these cases that could explain the development of
CSBS.
6.2. Loss-of-function mutations in CLMP cause recessive CSBS
In seven CSBS patients from ﬁve unrelated families, different homo-
zygous and compound heterozygous loss-of-function mutations have
been identiﬁed in the gene encoding for the Coxsackie- and adenovirus
receptor-like membrane protein (CLMP) [2]. The reported length of the
small intestine of these patients was 30 to 54 cm and they all presented
malrotation of the bowel. Neuronal intestinal dysplasia was reported in
twopatients (fromone family)with amore complexmutation, presum-
ably an inversion [2,20].
CLMP, located on chromosome 11 (11q24.1), encodes a transmem-
brane protein that co-localizes with tight junction proteins and acts as
an adhesion molecule [2,45]. It is expressed in the intestine during dif-
ferent stages of human development, and knockout of its orthologue
in zebraﬁsh resulted in developmental defects of several organs, includ-
ing the intestine. As tight junction proteins play an important role in
proliferation [22,46], we hypothesised that loss-of-function of CLMP
results in less proliferation of the small intestinal cells duringhumande-
velopment, leading to a shortened small intestine at birth [2]. Recently,
this hypothesis was tested using an in vitro approach where a mutant
CLMP (V124D), was over-expressed in a human intestinal epithelial
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to the cytoplasm [2], but in vitro assays failed to conﬁrm the role of
CLMP in cell viability, proliferation and migration in this cell line [47].
Thus, the role of CLMP in small intestinal development and its function
still remain unclear.
6.3. Mutations in FLNA cause X-linked CSBS
Mutations in Filamin A (FLNA) have been associated with a wide
spectrum of disorders characterized by a variable phenotype. Loss-of-
function mutations are found in patients with bilateral periventricular
nodular heterotopia, a neuronal migration disorder characterized by
seizures affecting mainly females, as it is often lethal in males [48]. Mu-
tations that alter the function of FLNA are associatedwith three different
disorders: otopalatodigital syndromes type 1 and 2, frontometaphyseal
dysplasia, and Melnick Needles syndrome. These syndromes constitute
a phenotypic spectrum that includes skeletal dysplasia, craniofacial-,
cardiac-, genito-urinary and intestinal anomalies, and central nervous
system defects [49]. In addition, missensemutations in FLNA are associ-
ated with X-linked cardiac valvular dystrophy [50,51]. CSBS has also
been described in some of the patients reported with loss-of-function
mutations in FLNA. However, these patients presentedmultiple congen-
ital anomalies and the short bowel was described as part of the disease
phenotype. A male patient, stillborn at 33 weeks of gestation, was re-
ported with a duplication of the ﬁrst 28 exons of FLNA. Prenatal ultra-
sounds showed normal growth with a single umbilical artery,
umbilical vein varix, and persistent dilatation of the bowel ﬁrst seen at
20 week gestation. These ﬁndings were conﬁrmed by an autopsy of
the foetus, which also detected a biﬁd uvula, an atrial septal defect,
and a malrotated short small intestine of 45 cm (164 cm would be the
expected length at this gestational stage). This duplication was also
identiﬁed in his mother, whowas diagnosed with a biﬁd uvula and pat-
ent ductus arteriosus, and in his maternal uncle, who hadmultiple con-
genital anomalies including a biﬁd uvula, intestinal malrotation,
undescended testes, partial agenesis of the corpus callosum, patent
ductus arteriosus, patent foramen ovale, ventricular septal defect and
periventricular heterotopia, and a small intestine measuring only
115 cm at the age of 10 years [27]. Another patient with a hemizygous
nonsensemutation in FLNA (c.7021CNT, Q2341X)was diagnosed prena-
tally with a left diaphragmatic defect, which caused a displacement of
the spleen, left hepatic lobe, and portions of the stomach and small
intestine into the left hemithorax. He also had dysmorphic facial fea-
tures, spina biﬁda occulta, natal tooth, periventricular heterotopia, a
posterior fossa arachnoid cyst, and proximally placed thumbs. He
died at 6 weeks of age and his small intestine measured only 68 cm
[27]. Recently, a family has been described with two affected male
siblings where a novel no-stop mutation in FLNA (c.7941_7942delCT,
p.(*2648Serext*100)) was identiﬁed upon genetic screening. The same
mutation was detected in their male cousin. These patients were diag-
nosed with CSBS, “wandering spleen”, periventricular nodular
heterotopia, persistent ductus arteriosus, and urinary tract abnormali-
ties [52]. All these reports conﬁrm that CSBS patients with mutations
in FLNA have, in general, multiple congenital anomalies in addition to
a shortened small intestine. Recently, however, a mutation in the sec-
ond exon of FLNA has been identiﬁed in three male patients (from two
different families) where CSBS appeared as an isolated symptom with-
out other major congenital anomalies [3]. In these patients, a two-
base-pair (bp) deletion in FLNA (c.16–17delCT)was identiﬁed. In anoth-
er male patient previously described with Chronic Idiopathic Intestinal
Pseudo-obstruction, a 2-bp deletion was also found in the second
exon of FLNA (c.65–66delAC). This patient was diagnosed with
malrotation, pyloric hypertrophy, intestinal pseudo-obstruction, and
CSBS [53,54]. In these four patients the length of the small intestine
ranged from 55 to 235 cm, and the age of diagnosis varied from 1 day
to 15 years [5,15,42], suggesting that in some cases, the small intestine
is less reduced in length and the diagnosis is made later in life whencompared to CSBS patients with CLMPmutations. These 2-bp deletions
are located between two nearby methionines at the N-terminus of
FLNA. Previous studies showed that translation of FLNA occurs from
both methionines, resulting in two protein isoforms [54]. In the pres-
ence of this 2-bp deletion the longer isoform is not translated anymore,
but there is still expression of the shorter FLNA isoform. We
hypothesised that this is the reason why these deletions are not lethal
for males in utero, and they only develop CSBS. Screening of exon 2 of
FLNA is therefore, recommended in such cases. In X-linked families
where CSBS is associated withmultiple congenital anomalies it is advis-
able to screen the entire FLNA for mutations.
FLNA encodes a cytoskeletal protein that binds to actin and has a
well-characterized role in the cytoplasm. It regulates cell shape by
cross-linking actin ﬁlaments, and plays an important role in cell signal-
ling andmigration in response to environmental changes [55]. A role for
FLNA has also been recently discovered in the nucleoli, where it inhibits
ribosomal RNA transcription [56]. FLNA has been reported to play an
important role in vascular development and cardiac morphogenesis
[57], but its role is still unclear in intestinal development. Nishita et al.
reported that FLNA is able to interact with the tyrosine kinase-like or-
phan receptor 2 (Ror2), and showed that this interaction is required
for ﬁlopodia formation and migration [58]. Since disruption of Ror2 ex-
pression has been shown to lead to a shortened small intestine in mice
[59], it is tempting to hypothesise that FLNAmutations leading to CSBS
disrupt the FLNA–Ror2 interaction and impair cell migration. However,
further studies are required to clarify the role of FLNA in intestinal
elongation.
7. Link between CLMP, FLNA and CSBS
We now know that mutations in CLMP and FLNA underlie CSBS pa-
thology [2,3]. However, it is still unclear whether CLMP and FLNA inter-
act with each other (directly or indirectly) and, therefore, whether
mutations in one of these two genes result in a similar course of events
during development of the small intestine. In this section, we discuss
different hypotheses to explain CSBS pathogenesis, and speculate
about a possible link between CLMP, FLNA and each of these
hypotheses.
7.1. Embryonic and intrauterine events
As mentioned in Section 5, during the seventh and tenth weeks of
embryonic development, the primitive digestive tube needs to return
to the intraumbilical coelom. Hamilton et al. suggested that in CSBS
this process is prevented. As a consequence, the primitive bowel is
forced to stay in the abdominal cavity and the cranial portion of the
bowel is not able to elongate, leading to a shortened small intestine
[1]. In another report, Aviram et al. observed the presence of bowel
loops inside the umbilical cord on a prenatal sonography of a patient
with CSBS, showing that the gut was able to elongate, but the return
of the intestine to the abdominal cavity was in fact delayed. They spec-
ulated that the incomplete dextral rotation and elongation of the bowel
caused this delay [38]. Delayed return of the intestine to the abdominal
cavity is also associated with volvulus and intestinal obstruction [60].
However, volvulus has only been described in four CSBS cases, and ad-
hesions, atresia, stenosis and scars are rarely found in CSBS patients. In
a case report of a premature neonate with an absent small bowel,
there was also no evidence of an abdominal wall defect or other intra-
abdominal anomalies on prenatal sonography [61]. Antenatal intussus-
ception followed by auto-anastomosis and auto-amputation is also sug-
gested as a cause of CSBS [12]. However, failure of intestinal elongation
can also be the cause, rather than the outcome of the observed
malrotation in CSBS patients [15]. In cases were auto-anastomoses
were found, intrauterine events like volvulus and infarction can be a
reasonable explanation for the shortened small intestine [4]. Another
hypothesis is that vascular events underlie CSBS [15]. Intrauterine
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and result in a decreased length of the remaining gut.
Considering the proposed embryologic and intrauterine events one
could hypothesise that CLMPmight play a role in these events. As men-
tioned earlier, tight junction proteins play an important role in prolifer-
ation [22,46]. Hence, we speculate that loss-of-function of CLMP results
in less proliferation of the small intestinal cells during human develop-
ment, leading to a shortened small intestine at birth. The processes and
pathways that may be disturbed by the loss of CLMP still remain
unknown.
FLNA can also be linked to embryologic and intrauterine events,
since it is known to play an important role in vascular development.
Patients with FLNAmutations have been reported with developmental
anomalies of the blood vessels [62,63], and omphalocoele [55]. An intra-
uterine vascular event causing small intestinal infarction [15] might,
therefore, be a reasonable explanation for the development of CSBS,
supporting the hypothesis that the developmental defect seen in CSBS
patients originates in the embryonic stage at which the bowel is accom-
modated in the intraumbilical coelom [1].
7.2. Lack of neurotransmitters and hormones
As abnormal peristalsis has been observed in some CSBS patients,
Sansaricq et al. hypothesised that these patients may lack synthesis of
neurotransmitters [18]. However, abnormal peristalsis is not described
in all patients. In another report, Schalamon et al. suggested that CSBS
patients lack growth-stimulating hormones like epidermal growth fac-
tor, insulin-like growth factor, and human growth hormone, but they
were unable to detect abnormal hormone levels in their patients [20].
How mutations in CLMP and FLNA can lead to disturbed or lack of
neurotransmitters is unclear. However, as these genes do not encode
or even have an (direct) effect on the production of neurotransmitters,
it is unlikely that a lack of neurotransmitters is the cause for the short-
ened small intestine observed in CSBS patients.
7.3. CLMP and FLNA
CSBS patients with mutations in CLMP seem to have a phenotype
more restricted to the intestine, whereas patients with mutations in
FLNA are more likely to have multiple congenital anomalies. However,
CSBS patientswith a deletion in the secondexon of FLNA are very similar
to patients with mutations in CLMP. This observation together with the
fact that both gene products are involved in similar cellular processes,
such as cell–cell contact and actin organisation, suggest that FLNA and
CLMP might be involved in the same protein network that is essential
for intestinal development.
FLNA is an actin-binding protein and its actin-binding domain is lo-
cated in its N-terminal region [55,64,65]. Gargiulo et al. showed abnor-
mal actin organisation in a lymphoblastoid cell line of a CSBS patient
with a c.65–66delAC deletion in FLNA [53]. Therefore, there is evidence
that the cytoskeletal actin organisation is disturbed in CSBS patients
with mutations in FLNA. However, it is still not knownwhether patients
with mutations in CLMP have a similar problem. Raschperger et al.
showed that CLMP co-localizes with actin ﬁlaments [45]. They speculat-
ed that CLMP interacts with a protein that directly binds to actin ﬁla-
ments, which would bring CLMP to the tight junctions by anchoring
CLMP to the actin cytoskeleton. They suggested that ZO-1 could be
such an interacting protein. As FLNA also binds to actin ﬁlaments and
is known to play a role in anchoring transmembrane proteins to the cy-
toskeleton for correct targeting to the cell membrane, such as integrin
beta and the cystic ﬁbrosis trans-membrane conductance regulator
(CFTR) [65,66], it is tempting to suggest that FLNA is the link between
CLMP and the actin cytoskeleton and is responsible for proper localiza-
tion of CLMP to the tight junctions (Fig. 3). Another possibility is that
FLNA plays a role in the internalization of CLMP into the plasma mem-
brane. As FLNA is known to control the internalization of the chemokinereceptor 2B in different dynamic membrane structures [67], one can
speculate that mutations in FLNA inﬂuence the expression levels of
CLMP on the plasma membrane. Further research is needed to deter-
mine whether CLMP and FLNA interact with each other as part of the
same protein network and, if so, which other proteins are involved in
this network. However, we cannot exclude the possibility that different
pathways underlie X-linked CSBS and autosomal recessive CSBS, with
different disease mechanisms leading to a similar disease phenotype.
It is also not known whether more genes are involved in the patho-
genesis of CSBS. We did not identify a mutation in all patients screened
for CLMP and the second exon of FLNA. However, we did not screen all
exons of FLNA in all patients analysed, which means that FLNA might
still play a role in disease development in some of these patients.
Based on the ﬁnding of an abnormal karyotypewith a ring chromosome
4 in oneCSBSpatientwithmultiple congenital anomalies [43], a gene on
the long arm of chromosome 4might also be involved. Further research
on the protein networks of CLMP and FLNAmight help ﬁndmore candi-
date genes for CSBS.
8. Mouse models for CSBS and intestinal elongation
In order to get new insights about the pathogenesis of CSBS, observa-
tions on CLMP and FLNA knockout animal models might be important.
They can help identify which cell types are affected, and also determine
if there is a general shortening or if speciﬁc parts of the intestine are af-
fected. To date, there is no mouse model available for CLMP, only a
zebraﬁsh model that was recently reported by our group [2]. In this
model, there was an overall reduction of the body length accompanied
by a drastic reduction in the size of the small intestine. Histological ﬁnd-
ings showed that there was also a signiﬁcant difference in gutmorphol-
ogy in the mutant ﬁsh, marked by the absence of goblet cells in themid
intestine. This result conﬁrmed the importance of CLMP for small intes-
tine development and elongation, but further investigation is required
to determine the role of CLMP in intestinal embryogenesis.
For FLNA, two mouse models have been reported: a conditional
knockout model, and a N-ethyl-N-nitrosourea induced model called
Dilp2 [57,68]. Both of them showed complete loss of Flna and resulted
in embryonic lethality. Vascular defects were also reported in both of
these models, and in one of them there was a delayed resorption of
the umbilical hernia [68]. Feng et al. further investigated the reasons as-
sociated to the vascular phenotype, and showed thatmigration andmo-
tility of different cell types were not affected in Flna-null embryos [57].
However, abnormal epithelial and endothelial organisation, and aber-
rant adherent junctions were observed in several tissues, including the
developing blood vessels, heart, and brain. A defect in intestinal elonga-
tion was not reported in any of these models, but it is possible that a
more detailed examination of these embryos could shed some light
into the role of FLNA in normal intestinal development.
With respect to intestinal elongation, several mouse models have
been reported with a shortened small intestine: Fgf9−/−; Shh−/−
Ihh−/−; Notch−/−;Wnt5a−/−; Ror2−/−; Sfrp1−/−Sfrp2−/−Sfrp5−/− and
Hlx−/− [59,69–74]. All these genes encode for proteins involved in high-
ly conserved signalling pathways known to play a crucial role in normal
embryonic development [69]. In this section,we describe these proteins
and associated pathways, and discuss their contribution towards the
elongation of the small intestine.
8.1. Fibroblast Growth Factor 9 (FGF9)
FGF9, also known as glia activating factor, is part of a large family of
polypeptide growth factors that are involved in a variety of biological
processes, such as embryonic development, cell growth, morphogene-
sis, tissue repair, tumour growth and invasion [75]. A knockout mouse
model for Fgf9 showed a disproportional small intestine, suggesting
that Fgf9 is particularly important for small intestinal morphogenesis.
However, this effect was only seen after embryonic day 14.5 (E14.5),
Fig. 3. Tight junction complexes and the possible link between CLMP and FLNA.
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stage embryogenesis [69]. The mechanism by which FGF9 regulates
this process is not totally known, but Geske et al. showed that this effect
might be due to a signiﬁcant increase of the transforming growth factor
beta (TGFβ) signalling pathway in the absence of FGF9 [69]. TGFβ sig-
nals are well-known to drive the transition of mesenchymal ﬁbroblasts
to myoblasts by activation of intermediate molecules, such as Smad2
and Smad3 [76]. However, this process ismostly seen as the small intes-
tine transitions to the postnatal period, when the proliferative proper-
ties of the mesenchymal ﬁbroblasts are less required. In the Fgf9−/−
mouse model, an increase in TGFβ signalling was detected at earlier
stages of embryogenesis, leading to a premature differentiation of the
mesenchymal ﬁbroblasts into myoﬁbroblasts and hence, to decreased
proliferation [69]. As a consequence, the normal elongation of the
small intestine was impaired.
8.2. Sonic (Shh) and Indian hedgehog (Ihh)
The mammalian family of lipid-modiﬁed hedgehog (Hh) signals are
composed of three members: Sonic hedgehog (Shh), Indian hedgehog
(Ihh), and Desert hedgehog (Dhh). Each of them is thought to signal
through a common mechanism that involves binding and inactivation
of Ptch1, a multi-pass transmembrane receptor. As a consequence, the
seven-pass membrane protein smoothened (Smo) is activated, leading
to a transcriptional response controlled by theGli family of transcription
factors [77]. Hh signalling is involved in proliferation, patterning and
differentiation of many tissues [78]. In the mammalian gut, Shh and
Ihh are known to be co-expressed in the endodermal epithelium from
early developmental stages (E8.5 ofmouse development) [79], and dys-
regulation of this pathway has already been implicated in both congen-
ital defects and cancers arising from the gastrointestinal tract [80,81].
However, mouse models where the expression of Shh or Ihh was
abolished only showed limited anomalies, likely due to functional re-
dundancy between these two proteins [77]. Mao et al. generated a dou-
ble mutant mouse model where expression of both Shh and Ihh was
blocked [70]. They showed that at E11.5 the digestive tract of doublemutant embryos was normal in shape, orientation and location in the
embryo, but was dramatically reduced in size relative to wild-type con-
trols. At the end of gestation this difference was even more striking, as
the intestine of Shh and Ihh null embryos completely failed to expand
[70]. However, the primary patterning of the gut into distinct organ seg-
ments was not affected. They further investigated the reasons behind
the phenotype and showed that double null embryos present a dramat-
ically reduced number of mesenchymal progenitors necessary for nor-
mal endodermal–mesenchymal interplay in the mammalian gut.
Vasculature integrity was intact and no signiﬁcant change in the levels
of necrotic and apoptotic markers were detected in these embryos, sug-
gesting that the decreased number of mesenchymal progenitors was a
primary effect of absent Hh signalling. Considering that intestinal
smooth muscle cells are derived from local mesenchymal progenitors,
the authors also investigated the effect of absent expression of Shh
and Ihh for smoothmuscle development [70]. They showed that double
mutant embryos do not express smooth muscle α actin (SMA), and
have impaired smoothmuscle differentiation due to reduced expansion
of the earlymesenchymal progenitor pool. Taken together, these results
showed that Hh signalling is a mitogenic factor necessary for expansion
of gut mesenchymal progenitors including those of the smooth muscle
compartment, and is thus, essential for embryonic gut development.
8.3. Notch
The Notch gene encodes for a transmembrane receptor protein
known to activate a signalling cascade critical for normal embryonic de-
velopment and tissue homeostasis [82]. In mammals there are four
Notch receptors (Notch 1–4), which upon ligand binding, trigger a se-
ries of proteolytic cleavages to release the intracellular domain of
Notch (NICD), a biologically active signal transducer [83]. NICD translo-
cates to the nucleus and binds to a transcription factor, recombining
binding protein suppressor of hairless (RBP-J), and to a co-activator,
Mastermind, activating transcription of several target genes involved
in cell proliferation or apoptosis [84]. The Notch signalling pathway is
widely used in different cell types and cellular processes. Therefore, it
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opmental disorders and cancers [85,86].
In the intestine, genetic analyses of zebraﬁsh and mouse mutants
have revealed a requirement of theNotch signalling pathway for cell ex-
pansion and proper lineage allocation of epithelial progenitors [87,88].
In addition, this pathway is particularly active in the developing intesti-
nal mesenchyme, speciﬁcally in sub-epithelial ﬁbroblasts, and its dys-
regulation was shown to play a role in intestinal elongation. Selective
disruption of the Notch pathway in the mesenchyme by the use of a
conditional knockout mouse for the effector gene Rbpj, or constitutive
activity of Notch by forced expression of NICD, led to a reduction of in-
testinal length [71]. In both cases, a progressive loss of sub-epithelial ﬁ-
broblastswas detected, but the phenotype observedwasmore severe in
the presence of constitutive Notch activation. A close inspection of the
mutant embryos showed that despite similarities in the phenotype,
the mechanisms leading to a reduction of sub-epithelial ﬁbroblasts
were different in each case. While the absence of Notch signalling led
to reduced proliferation of sub-epithelial ﬁbroblasts but no signiﬁcant
increase in apoptosis, over-activation of this pathway resulted in apo-
ptosis, and consequently cell death [71]. These observations showed
that the Notch signalling plays a critical role in the development of the
intestinal mesenchyme, and revealed that tight regulation of this path-
way is needed to ﬁne-tune its effects during intestinal elongation.
8.4. Wnt5a
The Wnt proteins are secreted glycoproteins known to activate var-
ious intracellular signalling cascades upon binding to their receptors,
Frizzled (Fzd) and/or transmembrane co-receptors, such as the lipopro-
tein receptor-related protein 5/6 (Lrp5/6), Ror2, and the related to re-
ceptor tyrosine kinase (Ryk) [89]. Wnt signalling pathway is divided
in two general categories – canonical and non-canonical – based on
transcriptional involvement of β-catenin. Independent of the pathway
activated, Wnt signalling is essential for diverse processes, including
cell fate, proliferation, differentiation,migration, polarity and asymmet-
ric cell division [90].
Wnt5a is one of the ligands involved in the activation of the non-
canonical Wnt signalling pathway. It is known to bind Ror2 and is re-
quired for normal embryogenesis, playing a pivotal role in the elonga-
tion process of several organs, including the small intestine [72,91,92].
Loss of either Wnt5a or Ror2 expression in mice was reported to lead
to a dramatic shortening of the small intestine [59,72]. Accordingly, ex-
pression levels of Wnt5a and Ror2 have been shown to peak during the
critical period ofmidgut elongation inmice, which is between E10.5 and
E13.5 [93]. Moreover, Bakker et al. showed that Wnt5a expression dur-
ing mouse intestinal embryogenesis is tightly orchestrated in certain
time frames, and overexpression or loss of expression during the critical
period of midgut elongation (before E13.5) leads to intestinal elonga-
tion defects [93]. It is still not clear howWnt5a and Ror2 regulate intes-
tinal elongation, but at the cellular level, they are known to be involved
in cell migration and proliferation [94]. Therefore, a decrease in cell pro-
liferation and migration induced by the absence of Wnt5a or Ror2,
might lead to a shortened small intestine.
Wnt5a is also known to activate theWnt/Jun N Kinase (JNK) signal-
ling pathway, deﬁned as the planar cell polarity pathway, as it mediates
orientation of the cell movements during development [95]. Previous
studies showed that JNK plays an irreplaceable role in preserving endo-
derm cell–cell adhesion and maintaining the stability of microtubules,
which are required for normal intestinal elongation. However,
activation of this pathway has to be tightly regulated for proper GI
tract development. The secreted Frizzled-related protein 1 (Sfrp1) has
been shown to directly interact withWnt5a, playing a key role regulat-
ing its activity [73]. Sfrp1 together with Sfrp2 and Sfrp5, belong to the
type 1 subfamily of Sfrp antagonists of the Wnt signalling [96]. Since
there is functional redundancy between themembers of each subfamily
[97], loss of Sfrp1, 2 and 5 in a compound mutant mouse model(Sfrp1−/− Sfrp2−/− Sfrp5+/−) led to dysregulation of the Wnt5a signal-
ling pathway detected by elevated levels of phosphorylated c-Jun in the
epithelium of the small intestine. As a consequence, mutant embryos
exhibited a shorten body axis and unsurprisingly, a dramatic reduction
in gut length [73]. On the other hand, the absence of active JNK signal-
ling led to dissociation of endoderm cells and perturbation of the cyto-
skeleton due to microtubule destabilisation, resulting as well, in an
impairment of gut elongation [98].8.5. HLX
The divergent murine homeo box gene Hlx encodes for a transcrip-
tion factor that during embryogenesis is mainly expressed in tissues of
mesodermal origin, such as visceral mesenchyme, skeletal myoblasts,
sclerotome and limb mesenchyme [99,100]. Hlx expression is detected
during mouse development at around E9.5 in the midgut and hindgut,
and from E10.5 to E12.5 in the liver, gall bladder, and gut. Homozygous
disruption ofHlx led to a dramatic impair of visceral organogenesis spe-
ciﬁcally of the liver (only reached 3% of its normal size) and the gut
(only reached a quarter of its normal length), suggesting that neither
of these organs were able to go through the dramatic expansion charac-
teristic of normal organogenesis in the absence of Hlx [74]. A detailed
examination of the Hlx−/− embryos showed a normal appearance
with characteristic midgut and hindgut structures at E10.5. However,
from E11.5 to E14.5 the extensive looping and midgut umbilical hernia
observed in wild-type embryos was absent in the mutants. The Hlx-/-
embryos exhibited only a single intestinal loop at E13.5 and E14.5, but
the mesenchyme became normally stratiﬁed into histologically distinct
layers [74]. The mechanism bywhich Hlx controls visceral organogene-
sis is still not well understood. Henscht et al. suggested that Hlx controls
a mesenchymal–epithelial interaction critical for liver and gut exten-
sion. This interaction is likely mediated by mitogenic factors or matrix
components secreted by themesenchyme, and is required for prolifera-
tion of both liver and gut epithelia [74].9. Concluding remarks
Genetic studies have identiﬁed two genes, CLMP and FLNA, thatwhen
mutated lead to the development of CSBS. Theseﬁndings have improved
the quality of genetic counselling for CSBS patients and made prenatal
diagnostics possible. However, the mechanisms by which CLMP and
FLNA lead to CSBS are still unknown.Mouse models have also identiﬁed
several other genes that are instrumental for intestinal elongation. All
these genes encode for proteins that play an instrumental role in
major signalling pathways required for embryonic development. How-
ever, the involvement of these genes in CSBS has not yet been reported.
Based on our current knowledge, it is difﬁcult to place CLMP and FLNA in
one of the complex networks involved in intestinal elongation, but it is
tempting to speculate that CLMP and FLNA can either control or be con-
trolled by one (ormore) of these signal transduction pathways. All these
ﬁndings provide new insights into CSBS pathogenesis, and represent a
ﬁrst step to identifymajor processes required for intestinal development
and elongation.Conﬂict of interest
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